Assessment of kidney injury during immune-targeted therapy (pembrolizumab + axitinib) in patients with metastatic renal cell carcinoma and solitary kidney
Open Access
- 6 August 2025
- journal article
- Published by Publishing House ABV Press in Cancer Urology
- Vol. 21 (2) , 33-41
Abstract
Aim. To assess the rate and type of kidney injury in the first 28 weeks of pembrolizumab and axitinib therapy after nephrectomy in patients with metastatic renal cell carcinoma and solitary kidney.Materials and methods. The retrospective study included 50 patients who previously underwent nephrectomy due to stage III–IV stage renal cell carcinoma. After nephrectomy prior to the start of antitumor therapy for cancer progression, 84 % of the patients were diagnosed with stage II and higher chronic kidney disease.Results. During antitumor drug treatment, acute kidney injury 14 and 28 weeks after the start of immune-targeted therapy was diagnosed in 4 % and 6 % of patients, respectively. Dynamics of the change in acute kidney injury in 28 weeks were not statistically significant (p = 0.983). Changes in serum creatinine, urea, and glomerular filtration rate were also insignificant. Statistically significant elevation of hemoglobin and hematocrit was observed during the 28 weeks of observation. Hemoglobin level increased from 128.1 g/L before the treatment to its maximal value of 141.7 g/L after the third injection of pembrolizumab (p 0.001).Conclusion. No significant kidney injury was observed during 28 weeks of observation in this single cohort study of patients with metastatic renal cell carcinoma after nephrectomy receiving pembrolizumab and axitinib.Keywords
This publication has 32 references indexed in Scilit:
- First and Second-line Treatments in Metastatic Renal Cell CarcinomaEuropean Urology, 2024
- Renal cell carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upAnnals of Oncology, 2024
- Risk Factors for Severe Hypertension and Proteinuria After Treatment With Vascular Endothelial Growth Factor Signaling Pathway Inhibitors Among Patients With CancerKidney International Reports, 2024
- Comparative safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: a systematic review and network meta-analysisEuropean Archives of Oto-Rhino-Laryngology, 2024
- Characterization and Management of Treatment-emergent Hepatic Toxicity in Patients with Advanced Renal Cell Carcinoma Receiving First-line Pembrolizumab plus Axitinib. Results from the KEYNOTE-426 TrialEuropean Urology Oncology, 2022
- Time to Resolution of Axitinib-Related Adverse Events After Treatment Interruption in Patients With Advanced Renal Cell CarcinomaClinical Genitourinary Cancer, 2021
- Axitinib plus pembrolizumab in patients with advanced renal-cell carcinoma: Long-term efficacy and safety from a phase Ib trialEuropean Journal of Cancer, 2021
- Contrast nephropathy in cancer patients receiving anti-VEGF therapy: a prospective studyInternational Journal of Clinical Oncology, 2020
- The nephrotoxicity of immune checkpoint inhibitor–based combinationsEuropean Journal of Cancer, 2018
- Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database ConsortiumEuropean Urology, 2014